Han et al. develop inhibitors that disrupt MYC/MAX heterodimerization, enhance MYC degradation, and impair MYC-driven gene expression. One compound exhibits potent anti-tumor efficacy in mice with good tolerability, increases tumor immune cell infiltration, and sensitizes tumors to anti-PD1 immunotherapy.
from Cancer Cell https://ift.tt/2PvncHU
from Cancer Cell https://ift.tt/2PvncHU